In an open-label prospective study, 19 patients with mBC refractory to at least one conventional therapy were treated with the hTERT peptide vaccine, and hTERT-specific CD8+ T cells were detected after vaccination in the peripheral blood of patients and exhibited effector functions in vitro, including proliferation, IFN-gamma production, and tumor lysis. This evidence concerns the gene CD8A and neoplasm.